Shopping Cart 0
Cart Subtotal
USD 0

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Karo Pharma AB (Karo Pharma), formerly Karo Bio AB, is a health care company that focuses on research and development of pharmaceutical products in the areas of cancer and autoimmune diseases. Its key research area involves nuclear receptors as target proteins for the development of new pharmaceuticals. Karo Pharma discovers drugs to target major diseases including autoimmune diseases such as multiple sclerosis; and multiple types of cancer, viral and bacterial infections. The company's projects are based on ROR gamma receptor and estrogen receptor. Its development pipeline also includes T268A Cold Spray which utilizes glucose oxidase enzyme in combination with glucose to fight against cold virus. Karo Pharma is headquartered in Huddinge, Stockholm, Sweden.

Karo Pharma AB (KARO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Karo Pharma AB, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 12

Private Equity 14

EQT VIII to Acquire Karo Pharma for USD652.6 Million 14

Partnerships 15

Karo Bio Enters Into Research Agreement With 4D Science 15

Licensing Agreements 16

Karo Pharma Enters into Licensing Agreement with Marinomed Biotech 16

Weifa Enters into Licensing Agreement with AFT Pharma 17

Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 18

Equity Offering 19

Karo Pharma Raises USD151.5 Million in Rights Offering of Shares 19

Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 20

Weifa Raises USD13.6 Million in Private Placement of Shares 21

Karo Bio Raises USD29 Million in Rights Offering of Shares 22

Aqualis to Raise USD116.7 Million in Private Placement of Shares 23

Aqualis to Raise USD16.7 Million in Rights Offering of Shares 24

Karo Bio Raises USD12 Million in Rights Offering of Shares 25

Karo Bio Raises USD1 Million in Private Placement of Shares 26

Aqualis Completes Private Placement Of Shares For USD 4 Million 27

Aqualis Completes Private Placement Of Shares For USD 4.7 Million 28

Aqualis Completes Rights Offering Of Shares For USD 9 Million 29

Karo Bio Completes Rights Offering of Shares for USD4.9 Million 30

Debt Offering 31

Aqualis to Raise USD66.7 Million in Public Offering of Bonds 31

Asset Transactions 32

Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 32

Acquisition 33

Karo Pharma Acquires Weifa 33

Karo Pharma Acquires 100% Stake in Medireduce 35

Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 36

Karo Bio Acquires Tanomed for USD2.3 Million 37

Aqualis Completes Acquisition of Weifa for USD183.6 Million 38

Karo Pharma AB-Key Competitors 39

Karo Pharma AB-Key Employees 40

Karo Pharma AB-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Financial Announcements 42

Jul 19, 2018: Karo pharma triples sales and profit in the second quarter 42

Apr 26, 2018: Karo Pharma Doubles Sales and Earnings in the First Quarter 44

Feb 22, 2018: Karo Pharma: Year-end Report 2017 45

Nov 02, 2017: Karo Pharma: Interim Report January- September 2017 46

Aug 24, 2017: Karo Pharma: Interim Report January-June 2017 48

May 10, 2017: Karo Pharma: interim report January-March-2017 49

Feb 28, 2017: Karo Pharma: Full Year Report 2016 50

Corporate Communications 51

Mar 23, 2018: Karo Pharma Supports Operation Smile 51

Product News 52

05/21/2018: UTILITY Therapeutics Receives Qualified Infectious Disease Product Designation from the U.S. FDA for Mecillinam 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Karo Pharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Karo Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 9

Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 12

EQT VIII to Acquire Karo Pharma for USD652.6 Million 14

Karo Bio Enters Into Research Agreement With 4D Science 15

Karo Pharma Enters into Licensing Agreement with Marinomed Biotech 16

Weifa Enters into Licensing Agreement with AFT Pharma 17

Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 18

Karo Pharma Raises USD151.5 Million in Rights Offering of Shares 19

Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 20

Weifa Raises USD13.6 Million in Private Placement of Shares 21

Karo Bio Raises USD29 Million in Rights Offering of Shares 22

Aqualis to Raise USD116.7 Million in Private Placement of Shares 23

Aqualis to Raise USD16.7 Million in Rights Offering of Shares 24

Karo Bio Raises USD12 Million in Rights Offering of Shares 25

Karo Bio Raises USD1 Million in Private Placement of Shares 26

Aqualis Completes Private Placement Of Shares For USD 4 Million 27

Aqualis Completes Private Placement Of Shares For USD 4.7 Million 28

Aqualis Completes Rights Offering Of Shares For USD 9 Million 29

Karo Bio Completes Rights Offering of Shares for USD4.9 Million 30

Aqualis to Raise USD66.7 Million in Public Offering of Bonds 31

Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 32

Karo Pharma Acquires Weifa 33

Karo Pharma Acquires 100% Stake in Medireduce 35

Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 36

Karo Bio Acquires Tanomed for USD2.3 Million 37

Aqualis Completes Acquisition of Weifa for USD183.6 Million 38

Karo Pharma AB, Key Competitors 39

Karo Pharma AB, Key Employees 40

Karo Pharma AB, Subsidiaries 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Karo Pharma AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Karo Pharma AB (Karo Pharma), formerly Karo Bio AB, is a health care company that focuses on research and development of pharmaceutical products in the areas of cancer and autoimmune diseases. Its key research area involves nuclear receptors as target proteins for the development of new pharmaceuticals. Karo Pharma discovers drugs to target major diseases including autoimmune diseases such as multiple sclerosis; and multiple types of cancer, viral and bacterial infections. The company's projects are based on ROR gamma receptor and estrogen receptor. Its development pipeline also includes T268A Cold Spray which utilizes glucose oxidase enzyme in combination with glucose to fight against cold virus. Karo Pharma is headquartered in Huddinge, Stockholm, Sweden.

Karo Pharma AB (KARO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Karo Pharma AB, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 12

Private Equity 14

EQT VIII to Acquire Karo Pharma for USD652.6 Million 14

Partnerships 15

Karo Bio Enters Into Research Agreement With 4D Science 15

Licensing Agreements 16

Karo Pharma Enters into Licensing Agreement with Marinomed Biotech 16

Weifa Enters into Licensing Agreement with AFT Pharma 17

Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 18

Equity Offering 19

Karo Pharma Raises USD151.5 Million in Rights Offering of Shares 19

Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 20

Weifa Raises USD13.6 Million in Private Placement of Shares 21

Karo Bio Raises USD29 Million in Rights Offering of Shares 22

Aqualis to Raise USD116.7 Million in Private Placement of Shares 23

Aqualis to Raise USD16.7 Million in Rights Offering of Shares 24

Karo Bio Raises USD12 Million in Rights Offering of Shares 25

Karo Bio Raises USD1 Million in Private Placement of Shares 26

Aqualis Completes Private Placement Of Shares For USD 4 Million 27

Aqualis Completes Private Placement Of Shares For USD 4.7 Million 28

Aqualis Completes Rights Offering Of Shares For USD 9 Million 29

Karo Bio Completes Rights Offering of Shares for USD4.9 Million 30

Debt Offering 31

Aqualis to Raise USD66.7 Million in Public Offering of Bonds 31

Asset Transactions 32

Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 32

Acquisition 33

Karo Pharma Acquires Weifa 33

Karo Pharma Acquires 100% Stake in Medireduce 35

Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 36

Karo Bio Acquires Tanomed for USD2.3 Million 37

Aqualis Completes Acquisition of Weifa for USD183.6 Million 38

Karo Pharma AB-Key Competitors 39

Karo Pharma AB-Key Employees 40

Karo Pharma AB-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Financial Announcements 42

Jul 19, 2018: Karo pharma triples sales and profit in the second quarter 42

Apr 26, 2018: Karo Pharma Doubles Sales and Earnings in the First Quarter 44

Feb 22, 2018: Karo Pharma: Year-end Report 2017 45

Nov 02, 2017: Karo Pharma: Interim Report January- September 2017 46

Aug 24, 2017: Karo Pharma: Interim Report January-June 2017 48

May 10, 2017: Karo Pharma: interim report January-March-2017 49

Feb 28, 2017: Karo Pharma: Full Year Report 2016 50

Corporate Communications 51

Mar 23, 2018: Karo Pharma Supports Operation Smile 51

Product News 52

05/21/2018: UTILITY Therapeutics Receives Qualified Infectious Disease Product Designation from the U.S. FDA for Mecillinam 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53


List Of Figure

List of Figures

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Karo Pharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Karo Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Karo Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 9

Karo Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10

Karo Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 12

EQT VIII to Acquire Karo Pharma for USD652.6 Million 14

Karo Bio Enters Into Research Agreement With 4D Science 15

Karo Pharma Enters into Licensing Agreement with Marinomed Biotech 16

Weifa Enters into Licensing Agreement with AFT Pharma 17

Karo Bio Enters into Licensing Agreement with Pelago Bioscience for CETSA 18

Karo Pharma Raises USD151.5 Million in Rights Offering of Shares 19

Karo Bio to Raise USD29.7 Million in Rights Offering of Preferred Shares 20

Weifa Raises USD13.6 Million in Private Placement of Shares 21

Karo Bio Raises USD29 Million in Rights Offering of Shares 22

Aqualis to Raise USD116.7 Million in Private Placement of Shares 23

Aqualis to Raise USD16.7 Million in Rights Offering of Shares 24

Karo Bio Raises USD12 Million in Rights Offering of Shares 25

Karo Bio Raises USD1 Million in Private Placement of Shares 26

Aqualis Completes Private Placement Of Shares For USD 4 Million 27

Aqualis Completes Private Placement Of Shares For USD 4.7 Million 28

Aqualis Completes Rights Offering Of Shares For USD 9 Million 29

Karo Bio Completes Rights Offering of Shares for USD4.9 Million 30

Aqualis to Raise USD66.7 Million in Public Offering of Bonds 31

Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 32

Karo Pharma Acquires Weifa 33

Karo Pharma Acquires 100% Stake in Medireduce 35

Karo Pharma Acquires BioPhausia from Medivir for USD95 Million 36

Karo Bio Acquires Tanomed for USD2.3 Million 37

Aqualis Completes Acquisition of Weifa for USD183.6 Million 38

Karo Pharma AB, Key Competitors 39

Karo Pharma AB, Key Employees 40

Karo Pharma AB, Subsidiaries 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Karo Pharma AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.